Within less than 2 weeks Brilacidin—Inflammatory Bowel Diseases Ulcerative Proctitis/Proctosigmoiditis Phase 2a Trial interim results for the second cohort
Brilacidin—Inflammatory Bowel Diseases Ulcerative Proctitis/Proctosigmoiditis (Phase 2a Trial) o This Proof-of-Concept trial includes enrolling 18 patients divided evenly into three cohorts. Review of safety data from the first 6 patients revealed that Brilacidin, administered for 6 weeks as a retention enema, at 50 mg once daily, appeared well-tolerated, with no measurable systemic absorption detected. Clinically meaningful improvements in symptoms were also demonstrated, as measured by physician assessments and patient reported outcomes, further supported with endoscopic evaluation. Brilacidin may show greater efficacy at higher dosing levels in the trial, which are comprised of 100 mg for the current cohort and 200 mg for the third cohort. Cellceutix believes that a successful trial creates an opportunity to explore Brilacidin for an array of other hard-to-treat Inflammatory Bowel Diseases that currently lack effective therapeutics.
o Upcoming Milestone: Cellceutix projects that an interim analysis of the second cohort will be completed in approximately two weeks.
News 
Market Data 
Discover 
